Entasis Therapeutics Holdings Inc.
DelistedCIK 1724344fmd_0E63VZ9ZNWRFVK7371N814EF87Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Mar 31, 2022, 19 periods
Latest annual · FY2019
Millions- Total revenues
- 7
- Operating income
- (52)
- Net income
- (47)
- Free cash flow
- (43)
Latest quarter · Q1 FY2022
Millions- Operating income
- (16)
- Net income
- (15)
- Free cash flow
- (14)
Entasis Therapeutics Holdings Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Operating income | -$52.3 million | -$54.2 million | 10-K 2022-03-03 · proof | |
| Net income | -$47.1 million | -$50.5 million | 10-K 2022-03-03 · proof | |
| Cash from operating activities | -$43 million | -$45.4 million | 10-K 2022-03-03 · proof | |
| Free cash flow | -$43 million | -$45.4 million | 10-K 2022-03-03 · proof | |
| Total assets | $40.9 million | $61.6 million | -33.5% | 10-K 2022-03-03 · proof |
| Total liabilities | $9.7 million | $9.3 million | +4.7% | 10-K 2022-03-03 · proof |
| Cash and cash equivalents | $32.3 million | $53.2 million | -39.3% | 10-K 2022-03-03 · proof |
- What was Entasis Therapeutics Holdings Inc.'s operating income in fiscal 2021?
- Entasis Therapeutics Holdings Inc. reported operating income of -$52.3 million for fiscal 2021 (the year ended Dec 31, 2021), against -$54.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What was Entasis Therapeutics Holdings Inc.'s net income in fiscal 2021?
- Entasis Therapeutics Holdings Inc. reported net income of -$47.1 million for fiscal 2021 (the year ended Dec 31, 2021), against -$50.5 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What was Entasis Therapeutics Holdings Inc.'s cash from operating activities in fiscal 2021?
- Entasis Therapeutics Holdings Inc. reported cash from operating activities of -$43 million for fiscal 2021 (the year ended Dec 31, 2021), against -$45.4 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What was Entasis Therapeutics Holdings Inc.'s free cash flow in fiscal 2021?
- Entasis Therapeutics Holdings Inc. reported free cash flow of -$43 million for fiscal 2021 (the year ended Dec 31, 2021), against -$45.4 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What are Entasis Therapeutics Holdings Inc.'s total assets?
- As of Dec 31, 2021, Entasis Therapeutics Holdings Inc. reported total assets of $40.9 million, against $61.6 million a year earlier (-33.5%). Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What are Entasis Therapeutics Holdings Inc.'s total liabilities?
- As of Dec 31, 2021, Entasis Therapeutics Holdings Inc. reported total liabilities of $9.7 million, against $9.3 million a year earlier (+4.7%). Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
- What are Entasis Therapeutics Holdings Inc.'s cash and cash equivalents?
- As of Dec 31, 2021, Entasis Therapeutics Holdings Inc. reported cash and cash equivalents of $32.3 million, against $53.2 million a year earlier (-39.3%). Source: the 10-K filed with the SEC on Mar 3, 2022. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1724344&period_type=annual&limit=5"Information only, not investment advice.